Tag

Health Care Archives | Page 119 of 137 | Smartkarma

Jul 15
0

Daily Brief Health Care: Piramal Enterprises and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Piramal Enterprises (PIEL IN): Demerger to Create a Differentiated and Niche Pharmaceutical Business

Piramal Enterprises (PIEL IN): Demerger to Create a Differentiated and Niche Pharmaceutical Business

By Tina Banerjee

  • Piramal Enterprises (PIEL IN) obtained shareholders nod for demerging its pharma business and consolidated under Piramal Pharma Limited (PPL). Later, PPL will be listed on India stock exchange.
  • PPL has a differentiated pharmaceutical business model, with three business verticals. CDMO, the largest revenue contributor, has track record of consistent above-market growth due to its niche and complex capabilities.  
  • Listed as a separate entity, PPL will see multiple expansion and command premium valuation over other Indian generic drug makers, due to its niche and limited competition portfolio.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free
Jul 14
0

Daily Brief Health Care: Giant Biogene Holding and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Giant Biogene Holding (GBH HK) Pre IPO: A Fundamentally Strong Company to Grab Market Opportunity

Giant Biogene Holding (GBH HK) Pre IPO: A Fundamentally Strong Company to Grab Market Opportunity

By Tina Banerjee

  • Giant Biogene Holding (GBH HK) has filed for a Hong Kong IPO for raising as much as $1 billion. The company is China’s largest supplier of collagen-based skincare products.
  • Through its dual-pronged “medical institution + mass consumer” sales strategy, the company has increased revenue to RMB1,553 million in 2021 from RMB956.7 million in 2019.
  • The collagen-based skincare market in China is expected to grow from RMB9.4 billion in 2022 to RMB77.5 billion in 2027, at a CAGR of 52.6%, thereby offering significant growth opportunity.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free
Jul 13
0

Daily Brief Health Care: Eisai Co Ltd, S&P 500, Huayiwang Technology and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Eisai Co (4523 JP): Trying Another Luck for Alzheimer’s Disease; Strengthening Presence in Oncology
  • U.S. Indexes Form Bear Flag Patterns Within Downtrends; Opportunities Within Health Care
  • Pre-IPO Huayiwang Technology – The Business Model Is Reasonable, but There Are Also Challenges

Eisai Co (4523 JP): Trying Another Luck for Alzheimer’s Disease; Strengthening Presence in Oncology

By Tina Banerjee

  • Eisai Co Ltd (4523 JP) has been granted priority review by the FDA for its second Alzheimer’s disease drug candidate, lecanemab. Approval is expected in Q1 2023.
  • Lecanemab could become the first anti-amyloid antibody to obtain full approval for Alzheimer’s disease in the U.S. Eisai is aiming for submission of lecanemab in Japan and EU this fiscal.   
  • Anticancer agent Lenvima is the largest selling drug of Eisai. Revenue from Lenvima increased 44% in FY22. The drug has taken top share in hepatocellular carcinoma market.

U.S. Indexes Form Bear Flag Patterns Within Downtrends; Opportunities Within Health Care

By Joe Jasper

  • We continue to view the price action over the past month as a bear market bounce in the S&P 500, Nasdaq 100 (QQQ), and Russell 2000 (IWM).
  • Each index appears to be forming a bearish flag pattern. Until the S&P 500, QQQ, and IWM can break above their YTD downtrends, we remain bearish.
  • We continue to believe that this bear market is being fueled by the rising U.S. dollar (DXY), rising 10-yr Treasury yield, and the move higher in WTI crude oil.

Pre-IPO Huayiwang Technology – The Business Model Is Reasonable, but There Are Also Challenges

By Xinyao (Criss) Wang

  • Huayiwang Technology (1985554D HK) is strong in its digital medical education solutions, which is the cornerstone business for the continuous expansion of other solution offerings and ecosystem.
  • HUAYIWANG charges service fees mainly from pharmaceutical companies, which could be a more sustainable profit model than charging from patients directly.
  • However, the increasing competition and potential risk of losing medical professionals could shake the foundations of HUAYIWANG’s business. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free
Jul 12
0

Daily Brief Health Care: Chugai Pharmaceutical, Cigna Corp, Shanghai MicroPort MedBot Group and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • TOPIX Rebalance: End-July Rebal Is $3.5bn One-Way – Some Big Sell Names
  • Blue Tower Asset Management Q2 2022 Commentary
  • MicroPort MedBot (2252.HK)- Lack an “anchor” for Valuation Due to Uncertainties in Commercialization

TOPIX Rebalance: End-July Rebal Is $3.5bn One-Way – Some Big Sell Names

By Travis Lundy

Blue Tower Asset Management Q2 2022 Commentary

By Fund Newsletters

  • Blue Tower Asset Management provides portfolio management services to individuals, financial advisers, and institutions.
  • With Q2 2022, the Blue Tower Global Value strategy composite returned 12.09% net of fees in the second quarter (12.41% gross) against a decline of -15.66% in the MSCI ACWI index.
  • The sanctions on Russian investments have dramatically increased the internal dispersion of our composite performance results.
  •  

MicroPort MedBot (2252.HK)- Lack an “anchor” for Valuation Due to Uncertainties in Commercialization

By Xinyao (Criss) Wang

  • To achieve massive sales expansion, surgical robots and consumables have to reduce price largely to enter NRDL reimbursement. This is at odds with expectations that they will generate high profits.
  • The actual market share gained and revenue generated by Medbot may fall far short of expectations, resulting in an inability to cover years of rapid growth in R&D/selling/administrative expenses.
  • Due to uncertainties on commercialization and profitability outlook, Medbot lacks an “anchor” for valuation.The large fluctuation in share price would continue. Surgical robots are not a good business for now.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free
Jul 11
0

Health Care: Akeso Biopharma Inc, Lotus Pharmaceutical and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Akeso Biopharma Placement (9926.HK) – The Concerns Behind and the Outlook
  • Lotus Pharmaceutical (1795 TT): Ready for Next Phase of Growth with New Ownership and Product Launch

Akeso Biopharma Placement (9926.HK) – The Concerns Behind and the Outlook

By Xinyao (Criss) Wang

  • The current stock price is not high. Akeso is reluctant to diluting its shareholders too much. So, it plans to raise just HK$576.65 million, which won’t bring any fundamental change.
  • Akeso (9926 HK)’s conservative management style, development mode, low cash balance and FDA’s “Guidance” on bispecific antibodies would limit the Company’s future development pace, commercialization, internationalization and valuation expansion prospects. 
  • We do not think Akeso is attractive at present, unless the Company could hit some big license-out deals, or IPO on SSE STAR Market to secure enough funds in advance. 

Lotus Pharmaceutical (1795 TT): Ready for Next Phase of Growth with New Ownership and Product Launch

By Tina Banerjee

  • Aztiq and Innobic have formally become the leading shareholder of  Lotus Pharmaceutical (1795 TT), with the controlling stake of 51%. New ownership will accelerate the growth and expansion of Lotus.
  • Lotus has created a niche for itself through its focus on oral oncology drug. Launch of Lenalidomide in 14 European countries drove 31% q/q growth in export revenue in Q1.
  • Continued strong uptake of the company’s newly acquired drug Cialis in Taiwan and bevacizumab biosimilar launch in Korea and Taiwan should boost its Asian business revenue.

Before it’s here, it’s on Smartkarma

Learn More
Jul 10
0

Health Care: Paramount Bed Holdings Co Lt and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Paramount Bed (7817 JP): Record High Revenue Clocked in FY22; New Management Target Announced

Paramount Bed (7817 JP): Record High Revenue Clocked in FY22; New Management Target Announced

By Tina Banerjee

  • Paramount Bed Holdings Co Lt (7817 JP) announced record high sales in FY22, driven by strong demand of hospital beds and achieved management target two year ahead of plan.
  • While near-term challenges including high input cost and semiconductor supply shortage negatively impact FY23 performance, Paramount aims to achieve 33% revenue growth and 50bps operating margin expansion during FY22–27.   
  • Paramount is a strong play on COVID recovery. The shares gained 15% since I published bullish note on the company on January 17, 2022. More stream is still left.   

Before it’s here, it’s on Smartkarma

Learn More
Jul 09
0

Health Care: Sri Trang Gloves (Thailand) Public Company Limited and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Sri Trang Gloves (STGT TB): 2022 Started On a Weak Note; Lower ASP Is Industry Wide Phenomena

Sri Trang Gloves (STGT TB): 2022 Started On a Weak Note; Lower ASP Is Industry Wide Phenomena

By Tina Banerjee

  • Sri Trang Gloves (Thailand) Public Company Limited (STGT TB) reported record high sales volume due to strong demand in existing markets and expansion into new markets.
  • However, lower ASP as a result of additional supply in the market, dragged down revenue and profitability of the company. No recovery in ASP is seen in near-term.
  • By leveraging on its locational advantage for NR glove, focusing on fast growing developing markets, and launching high-margin surgical glove in Thailand, STGT is well-positioned to outpace its Malaysian peers.

Before it’s here, it’s on Smartkarma

Learn More
Jul 08
0

Health Care: Supermax Corp, Assertio Holdings and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Supermax Corp (SUCB MK): Quickly Mending the Damage; Soft Demand Outlook Remains the Main Overhang
  • ASRT: Rolling Up with Buy Initiation

Supermax Corp (SUCB MK): Quickly Mending the Damage; Soft Demand Outlook Remains the Main Overhang

By Tina Banerjee

  • Supermax Corp (SUCB MK) is facing import ban from the U.S. and Canada. Recently, Norway wealth fund has put the investment in the company under observation for two years.
  • Since 2019, Supermax is being alleged for the poor living and working conditions experienced by its employees. Recently the company has aligned itself to the ILO standard.
  • However, COVID-driven demand of glove is cooling off. Even upon this, excess capacity is bringing down the average selling price, thereby making the earnings outlook uncertain for glove manufacturers.   

ASRT: Rolling Up with Buy Initiation

By Hamed Khorsand

  • ASRT is classic roll-up story where it is leveraging cash flow from one drug to create a portfolio of multiple drugs
  • ASRT has managed to stay under investor radars through acquisitions of drugs with small revenue streams. The revenue is starting to add up 
  • ASRT can use its digital marketing approach to grow earnings and free cash flow from each of the drugs it acquires

Before it’s here, it’s on Smartkarma

Learn More
Jul 07
0

Health Care: Medy Tox Inc and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Medy Tox Inc (086900 KS): Legal Battle Continues; Muted Recovery in Export Revenue

Medy Tox Inc (086900 KS): Legal Battle Continues; Muted Recovery in Export Revenue

By Tina Banerjee

  • The U.S. International Trade Commission is starting an official investigation based on Medy Tox Inc (086900 KS)’s complaint against Hugel for the alleged theft of its botulinum toxin strain.  
  • The verdict is expected in H12023. Hugel is expected to receive FDA approval for botulinum toxin by the end of 2022, while Medytox plans to file to FDA in H12023.  
  • Medytox’s export revenue has still not recovered. However, Q1 sales jumped 25%, on the back of 89% increase in domestic revenue. Medytox shares has declined 20% YTD.

Before it’s here, it’s on Smartkarma

Learn More
Jul 06
0

Health Care: Shionogi & Co, Gaush Meditech and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Shionogi & Co (4507 JP): Ready To Cash-In On COVID-Related Efforts; Long-Term Growth Drivers Added
  • Pre-IPO Gaush Meditech – The “Middlemen” Have Many Challenges

Shionogi & Co (4507 JP): Ready To Cash-In On COVID-Related Efforts; Long-Term Growth Drivers Added

By Tina Banerjee

  • Shionogi & Co (4507 JP), an established global name in infectious diseases, is banking on COVID-related products to achieve accelerated double-digit revenue growth in current fiscal.
  • Shionogi applied for the domestic marketing of its COVID-19 oral drug and signed a basic agreement with the government, which is expected to purchase 1 million courses immediately after approval.
  • It has a stable revenue stream from HIV franchise. Apart from infectious diseases, Shionogi has multiple late-stage candidates in psycho-neurological diseases and other new growth areas, including oncology and cardiology.

Pre-IPO Gaush Meditech – The “Middlemen” Have Many Challenges

By Xinyao (Criss) Wang

  • Gaush Meditech (GMT HK) is a leading total solution provider of ophthalmic medical devices industry.
  • The irreplaceability of Gaush in the whole industrial chain is actually not high based on its current business model.The proprietary product business may also need to face different policy risks.
  • Together with other uncertainties such as increasing market competition and medical reform policy in China, we are conservative about Gaush’s outlook at the current stage.  

Before it’s here, it’s on Smartkarma

Learn More